Journal article

Determining HER2 (ERBB2) amplification status in women with breast cancer: final results from the Australian in situ hybridisation program

Adrienne L Morey, Belinda Brown, Gelareh Farshid, Stephen B Fox, Glenn D Francis, Glenda McCue, Vita von Neumann-Cosel, Michael Bilous

Pathology | ELSEVIER SCIENCE BV | Published : 2016

Grants

Funding Acknowledgements

Medical writing services from WriteSource Medical Pty Ltd were funded by Roche Products Pty Ltd. This study was funded by Roche Products Pty Ltd, Australia. ALM has held a consultancy/advisory role with Roche Products Pty Ltd and Pfizer; GF has held a consultancy/advisory role with the Australian HER2 Advisory Board; SBF has held a consultancy/advisory role with Roche Products Pty Ltd; GDF has received honoraria from Roche Products Pty Ltd and has held a consultancy/advisory role with Roche Products Pty Ltd, Astra Zeneca, Merck Serrono and Pfizer; GM has held a consultancy role with Roche Products Pty Ltd; VvN-C is an employee of Roche Products Pty Ltd, which markets trastuzumab; MB has held a consultancy/advisory role with F. Hoffmann-La Roche.